Burioni Roberto, Canducci Filippo, Mancini Nicasio, Clementi Nicola, Sassi Monica, De Marco Donata, Saita Diego, Diotti Roberta Antonia, Sautto Giuseppe, Sampaolo Michela, Clementi Massimo
Laboratorio di Microbiologia e Virologia, Università Vita-Salute San Raffaele, Milano, Italy.
New Microbiol. 2009 Oct;32(4):319-24.
The pandemic caused by the new H1N1 swine-origin influenza virus (S-OIV) strain is a worldwide health emergency and alternative therapeutic and prophylactic options are greatly needed. Two human monoclonal antibody Fab fragments (HMab) neutralizing the novel H1N1 influenza strain at very low concentrations were cloned from a patient who had a broad-range anti-H1N1 serum neutralizing activity. The two HMabs neutralized S-OIV with an IC50 of 2.8 and 4 microg/mL. The genes coding for the neutralizing HMabs could be used for generating full human monoclonal IgGs that can be safely administered with the potentially of representing a novel drug to be used in the prophylaxis and the treatment of this human infection. This is the first report of molecular cloning of human monoclonal antibodies against the new pandemic swine-origin influenza virus.
由新型H1N1猪源流感病毒（S-OIV）毒株引起的大流行是一场全球卫生紧急事件，因此急需替代性治疗和预防方案。从一名具有广泛抗H1N1血清中和活性的患者体内克隆出了两种能在极低浓度下中和新型H1N1流感毒株的人单克隆抗体Fab片段（HMab）。这两种HMab对S-OIV的半数抑制浓度（IC50）分别为2.8和4微克/毫升。编码中和性HMab的基因可用于制备全人源单克隆IgG，其具有安全给药的潜力，有可能成为用于预防和治疗这种人类感染的新型药物。这是关于针对新型大流行性猪源流感病毒的人单克隆抗体分子克隆的首次报道。
